Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil

Journal of Hepatology

Volumn 55, Issue 4, 2011, Pages 858-865

  Hsu, Chao Yu ^a,b   Shen, Ying Chun ^a,b   Yu, Chih Wei ^a,b   Hsu, Chiun ^b   Hu, Fu Chang ^b   Hsu, Chih Hung ^b   Chen, Bang Bin ^a,b   Wei, Shwu Yuan ^a,b   Cheng, Ann Lii ^a,b   Shih, Tiffany Ting Fang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Metronomic chemotherapy; Sorafenib; Tegafur uracil; Vascular response

Indexed keywords

SORAFENIB; UFT;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; CANCER SURVIVAL; CLINICAL ARTICLE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PYRIDINES; TEGAFUR; URACIL; YOUNG ADULT;

EID: 80052948925     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.01.032     Document Type: Article

References (38)

1. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
2. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
3. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
4. M.J. Ratain, and G. Eckhardt Phase II studies of modern drugs directed against new targets: if you are fazed too, then resist RECIST J Clin Oncol 22 2004 4442 4445 (Pubitemid 41185107)
5. C.H. Hsu, T.S. Yang, C. Hsu, H.C. Toh, R.J. Epstein, and L.T. Hsiao Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Br J Cancer 102 2010 981 986
6. C.H. Hsu, Y.C. Shen, Z.Z. Lin, P.J. Chen, Y.Y. Shao, and Y.H. Ding Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma J Hepatol 53 2010 126 131
7. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat Rev Cancer 4 2004 423 436 (Pubitemid 38745528)
8. L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, and D. Wilkie Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858 (Pubitemid 46094197)
9. P. Newell, A. Villanueva, and J.M. Llovet Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials J Hepatol 49 2008 1 5
10. J.K. Willmann, N. van Bruggen, L.M. Dinkelborg, and S.S. Gambhir Molecular imaging in drug development Nat Rev Drug Dis 7 2008 591 607 (Pubitemid 351927724)
11. L.W. Dobrucki, E.D. de Muinck, J.R. Lindner, and A.J. Sinusas Approaches to multimodality imaging of angiogenesis J Nucl Med 51 2010 1S 14S
12. J.P.B. O'Connor, A. Jackson, G.J.M. Parker, and G.C. Jayson DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents Br J Cancer 96 2007 189 195 (Pubitemid 46160619)
13. M.O. Leach, K.M. Brindle, J.L. Evelhoch, J.R. Griffiths, M.R. Horsman, and A. Jackson The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br J Cancer 92 2005 1599 1610 (Pubitemid 40756468)
14. J. Evelhoch, M. Garwood, D. Vigneron, M. Knopp, D. Sullivan, and A. Menkens Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report Cancer Res 65 2005 7041 7044 (Pubitemid 41161229)
15. J.L. Evelhoch Key factors in the acquisition of contrast kinetic data for oncology J Magn Reson Imaging 10 1999 254 259 (Pubitemid 29463107)
16. T. Yau, P. Chan, K.K. Ng, S.H. Chok, T.T. Cheung, and S.T. Fan Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response Cancer 115 2009 428 436
17. D. Strumberg, J.W. Clark, A. Awada, M.J. Moore, H. Richly, and A. Hendlisz Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 2007 426 437 (Pubitemid 46698720)
18. P.M. Hoff, and R. Pazdur UFT plus oral leucovorin: a new oral treatment for colorectal cancer Oncologist 3 1998 155 164 (Pubitemid 28307446)
19. P.S. Tofts, G. Brix, D.L. Buckley, J.L. Evelhoch, E. Henderson, and M.V. Knopp Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols J Magn Reson Imaging 10 1999 223 232 (Pubitemid 29463104)
20. B. Morgan, A.L. Thomas, J. Drevs, J. Hennig, M. Buchert, and A. Jivan Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol 21 2003 3955 3964 (Pubitemid 46606209)
21. J. Drevs, P. Siegert, M. Medinger, K. Mross, R. Strecker, and U. Zirrgiebel Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors J Clin Oncol 25 2007 3045 3054 (Pubitemid 47218051)
22. C. Roberts, B. Issa, A. Stone, A. Jackson, J.C. Waterton, and G.J. Parker Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies J Magn Reson Imaging 23 2006 554 563
23. Y.Y. Shao, Z.Z. Lin, C. Hsu, Y.C. Shen, C.H. Hsu, and A.L. Cheng Early alpha-fetoprotein response predicts treatment efficacy of anti-angiogenic systemic therapy in patients with advanced hepatocellular carcinoma Cancer 116 2010 4590 4596
24. A.D. Smith, M.L. Lieber, and S.N. Shah Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT AJR Am J Roentgenol 194 2010 157 165
25. M. Lamuraglia, B. Escudier, L. Chami, B. Schwartz, J. Leclre, and A. Roche To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound Eur J Cancer 42 2006 2472 2479 (Pubitemid 44442955)
26. N. Lassau, S. Koscielny, L. Chami, M. Chebil, B. Benatsou, and A. Roche Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification - preliminary results Radiology 258 2011 291 300
27. O.M. Hahn, C. Yang, M. Medved, G. Karczmar, E. Kistner, and T. Karrison Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma J Clin Oncol 26 2008 4572 4578
28. K.T. Flaherty, M.A. Rosen, D.F. Heitjan, M.L. Gallagher, B. Schwartz, and M.D. Schnall Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma Cancer Biol Ther 7 2008 496 501 (Pubitemid 351847022)
29. E.T. Lam, M.D. Ringel, R.T. Kloos, T.W. Prior, M.V. Knopp, and J. Liang Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer J Clin Oncol 28 2010 2323 2330
30. R.T. Kloos, M.D. Ringel, M.V. Knopp, N.C. Hall, M. King, and R. Stevens Phase II trial of sorafenib in metastatic thyroid cancer J Clin Oncol 27 2009 1675 1684
31. A.X. Zhu, D.V. Sahani, D.G. Duda, E. di Tomaso, M. Ancukiewicz, and O.A. Catalano Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 2009 3027 3035
32. Murphy PS, Roberts C, Whitcher B, Stornanti F, Gauvin J, Yau T, et al. Vascular response of hepatocellular carcinoma to pazopanib measured by dynamic contrast-enhanced MRI: pharmacokinetic and clinical activity correlations. Proceedings of International Society for Magnetic Resonance in Medicine (ISMRM) 2010 annual meeting, Stockholm, Sweden, May 1-7; 2010. p. 2720.
33. S.M. Galbraith, R.J. Maxwell, M.A. Lodge, G.M. Tozer, J. Wilson, and N.J. Taylor Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J Clin Oncol 21 2003 2831 2842 (Pubitemid 46621830)
34. J.P.B. O'Connor, R.A.D. Carano, A.R. Clamp, J. Ross, C.C.K. Ho, and A. Jackson Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Clin Cancer Res 15 2009 6674 6682
35. A. Hormigo, P.H. Gutin, and S. Rafii Tracking normalization of brain tumor vasculature by magnetic Imaging and proangiogenic biomarkers Cancer Cell 11 2007 6 8 (Pubitemid 46054523)
36. T.E. Yankeelov, and J.C. Gore Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples Curr Med Imaging Rev 3 2009 91 107 (Pubitemid 46773870)
37. A. Jackson, J.P.B. O'Connor, G.J.M. Parker, and G.C. Jayson Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging Clin Cancer Res 13 2007 3449 3459 (Pubitemid 46955104)
38. C. Hsu, Y.C. Shen, C.C. Cheng, F.C. Hu, and A.L. Cheng Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design Contemp Clin Trials 31 2010 55 61